IL4R and neoplasm: Systemic administration of IL4R‐Exo (si/mi) showed effective tumor targeting by re‐educating TAM into M1‐type macrophages and promoting the activity of immunostimulatory cells to remodel TME, resulting in inhibited tumor growth.173